{"id":"NCT00958438","sponsor":"Regeneron Pharmaceuticals","briefTitle":"PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2009-08-13","resultsPosted":"2017-04-28","lastUpdate":"2017-04-28"},"enrollment":248,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rilonacept","otherNames":[]},{"type":"DRUG","name":"Rilonacept","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rilonacept 80 mg","type":"EXPERIMENTAL"},{"label":"Rilonacept 160 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who are beginning allopurinol treatment for gout. Participants will participate in this study for approximately 22 weeks. Rilonacept was being studied for use in preventing allopurinol-induced gout flares.","primaryOutcome":{"measure":"Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)","timeFrame":"Day 1 to Day 113 (Week 16)","effectByArm":[{"arm":"Placebo","deltaMin":1.23,"sd":1.57},{"arm":"Rilonacept 80 mg","deltaMin":0.35,"sd":0.67},{"arm":"Rilonacept 160 mg","deltaMin":0.34,"sd":0.86}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":61,"countries":["Germany","India","Indonesia","South Africa","Taiwan"]},"refs":{"pmids":["23485476"],"seeAlso":["http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=501081761&QV1=RILONACEPT","http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=000315300&QV1=ALLOPURINOL","http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=017795210&QV1=ALLOPURINOL+SODIUM"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":82},"commonTop":["Influenza","Injection site erythema","Accidental overdose","Nasopharyngitis","Headache"]}}